Polaryx Therapeutics, Inc. 8-K

What Happened

• Polaryx Therapeutics, Inc. announced a private placement under a Securities Purchase Agreement dated May 27, 2026, and closed on May 28, 2026. The Company sold 2,502,696 shares of common stock for aggregate gross proceeds of $10.0 million (weighted average price ≈ $4.00 per share). The issuance represents about 5.3% of the Company’s outstanding shares immediately prior to the placement.
• MStone Partners Healthcare Limited, the Company’s largest stockholder, participated, buying 88,453 shares for $360,000. The per-share purchase price varied by investor commitment (ranging from $3.70 up to $4.10 per share depending on committed amount).

Key Details

• Closing date: May 28, 2026; Purchase Agreement dated May 27, 2026.
• Shares issued: 2,502,696 common shares; gross proceeds: $10,000,000; weighted average price ≈ $4.00/share.
• Dilution: issuance equals ~5.3% of shares outstanding immediately prior to the offering.
• Use of proceeds: expected to fund the Phase 2 proof-of-concept basket trial SOTERIA (PLX-200-600), plus working capital and general corporate purposes.
• Securities treatment: Shares issued in a private placement relying on Section 4(a)(2) and/or Regulation S; resale restricted absent registration or an applicable exemption.

Why It Matters

• The financing provides near-term cash to advance Polaryx’s Phase 2 SOTERIA trial and supports operations without immediate public equity raises. Investors should note the 5.3% immediate dilution and the private-sale restrictions on the new shares. The participation by the largest shareholder is a signal of insider support, while the weighted average price ($4.00) sets a recent private-market valuation reference point.